Enalapril formulations
DC CAFCFirst Claim
Patent Images
1. A stable oral liquid formulation, comprising:
- (i) about 1 mg/ml enalapril maleate;
(ii) a buffer comprising about 1.82 mg/ml citric acid and about 0.15 mg/mL sodium citrate dihydrate;
(iii) about 1 mg/ml of a preservative that is sodium benzoate; and
(iv) water;
wherein the pH of the formulation is less than about 3.5; and
wherein the formulation is stable at about 5±
3°
C. for at least 12 months;
wherein the stable oral liquid formulation has about 95% or greater of the initial enalapril amount and about 5% w/w or less total impurities or related substances at the end of the given storage period.
9 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
47 Citations
20 Claims
-
1. A stable oral liquid formulation, comprising:
-
(i) about 1 mg/ml enalapril maleate; (ii) a buffer comprising about 1.82 mg/ml citric acid and about 0.15 mg/mL sodium citrate dihydrate; (iii) about 1 mg/ml of a preservative that is sodium benzoate; and (iv) water; wherein the pH of the formulation is less than about 3.5; and wherein the formulation is stable at about 5±
3°
C. for at least 12 months;wherein the stable oral liquid formulation has about 95% or greater of the initial enalapril amount and about 5% w/w or less total impurities or related substances at the end of the given storage period. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 19)
-
-
11. A stable oral liquid formulation, comprising:
-
(i) about 19.3% (w/w of solids) enalapril maleate; (ii) a buffer comprising about 35.2% (w/w of solids) citric acid and about 2.9% (w/w of solids) sodium citrate dihydrate; (iii) about 19.3% (w/w of solids) of a preservative that is sodium benzoate; and (iv) water; wherein the pH of the formulation is less than about 3.5; and wherein the formulation is stable at about 5±
3°
C. for at least 12 months;wherein the stable oral liquid formulation has about 95% or greater of the initial enalapril amount and about 5% w/w or less total impurities or related substances at the end of the given storage period. - View Dependent Claims (12, 13, 14, 15, 16, 17, 20)
-
-
18. A stable oral liquid formulation, consisting essentially of:
-
(i) about 1 mg/ml enalapril maleate; (ii) about 0.70 mg/ml of a sweetener that is sucralose; (iii) a buffer comprising about 1.82 mg/ml citric acid and about 0.15 mg/ml sodium citrate dihydrate; (iv) about 1 mg/ml of a preservative that is sodium benzoate; (v) a flavoring agent; and (vi) water; wherein the pH of the formulation is less than about 3.5 adjusted by sodium hydroxide or hydrochloric acid if needed; and wherein the formulation is stable at about 5±
3°
C. for at least 12 months;wherein the stable oral liquid formulation has about 95% or greater of the initial enalapril amount and about 5% w/w or less total impurities or related substances at the end of the given storage period.
-
Specification